arcoris bio, a Swiss life science research tools and in vitro diagnostics company, announced a distribution partnership with Europa Biosite, a leading di...
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding ...
Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, announced the expansion of its mu...
In a significant move to advance the treatment of patients with inflammatory breast cancer (IBC), Dana-Farber Cancer Institute, The Ohio State Univ...
The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. Hepatitis D affects nearly 12 million o...
Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector Sarclisa Escena admini...
While we will need to wait for the National Commission into the Regulation of AI in Healthcare's recommendations later this summer, and then the MH...
Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), an innovative biopharmaceutical company specializing in the development of innovative dr...
Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, and EpiCypher®, the leading provider of ChIC/CU...
TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Europe for the treatment of...
Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action Combines oncology expertise of ...
Following encouraging earlier-phase clinical data, the Company is advancing its acne trial ahead of schedule while maintaining atopic dermatitis global P...
Phase I results provide platform-level validation supporting AdJane's broader development programs in pandemic preparedness, respiratory infectious disea...
Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Diva...
© 2026 Biopharma Boardroom. All Rights Reserved.
